GlassScriptPhysician profile
Elliott Carter
NPI 1972167617
$804.81
in general payments reported to CMS, 2019-2025
16 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $183 · 2024: $348 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $804.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $230.14 | 2023-2024 | Veozah |
| Biogen, INC. | $105.44 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $83.01 | 2023 | Summit Doppler |
| Sumitomo Pharma America, INC. | $77.78 | 2023-2025 | Gemtesa, Myfembree |
| Exeltis, USA INC. | $64.61 | 2023-2025 | Slynd |
| Smith+Nephew, INC. | $37.65 | 2025 | Stravix |
| Hologic Sales and Service, LLC | $25.10 | 2023 | Aptima |
| Baxter Healthcare | $23.83 | 2024 | Seprafilm |
| Boston Scientific Corporation | $22.03 | 2025 | General - Female Sui |
| Merck Sharp & Dohme LLC | $21.67 | 2024 | Gardasil 9, Gardasil |
| Lilly USA, LLC | $21.05 | 2025 | Zepbound |
| Coloplast Corp | $19.88 | 2025 | |
| Shield Therapeutics INC | $18.50 | 2025 | |
| Sage Therapeutics, LLC | $18.26 | 2024 | |
| Lsi Solutions INC | $18.11 | 2024 | Fornisee |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliott Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.